malaria vaccine
Community perceptions of a malaria vaccine in the Kintampo districts of Ghana
10
Advances and challenges in malaria vaccine development
12
Awareness, perceptions and intent to comply with the prospective malaria vaccine in parts of South Eastern Nigeria
7
Stakeholders’ opinions and questions regarding the anticipated malaria vaccine in Tanzania
13
Adjuvants in malaria vaccine development strategies: a review
8
Policy analysis for deciding on a malaria vaccine RTS,S in Tanzania
7
Malaria vaccine research and development: the role of the WHO MALVAC committee
11
Assessment of parental perception of malaria vaccine in Tanzania
6
Seasonal vaccination against malaria: a potential use for an imperfect malaria vaccine
5
Acceptance of a malaria vaccine by caregivers of sick children in Kenya
12
Lack of allele specific efficacy of a bivalent AMA1 malaria vaccine
13
The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti circumsporozoite protein antibody avidity in African infants
6
Antibodies to malaria vaccine candidates are associated with chloroquine or sulphadoxine/pyrimethamine treatment efficacy in children in an endemic area of Burkina Faso
6
Malaria vaccine efficacy: the difficulty of detecting and diagnosing malaria
10
Large screen approaches to identify novel malaria vaccine candidates
10
Prime boost strategies for malaria vaccine development
9
Stable malaria incidence despite scaling up control strategies in a malaria vaccine testing site in Mali
9
Assessment of Pfs25 expressed from multiple soluble expression platforms for use as transmission blocking vaccine candidates
12
Chemically attenuated blood-stage Plasmodium yoelii parasites induce long-lived and strain-transcending protection
15
Genetic diversity of the merozoite surface protein 3 gene in Plasmodium falciparum populations in Thailand
15